Alemtuzumab

Alemtuzumab Uses, Dosage, Side Effects, Food Interaction and all others data.

Humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein,CD52. The Campath-1H antibody is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Campath is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin.

Campath is used to treat leukemia by exploiting antibody mediated lysis of CD52 presenting cells. The CD52 antigen is a cell surface protein found on essentially all B and T lymphocytes, a majority of monocytes, macrophages and most granulocytes. The CD52 antigen is not present on erythrocytes or hematopoetic stem cells. In leukemia there is an excess of B and T cells, so Campath permits selective reduction of lymphocyte populations.

Table Of contents

• Alemtuzumab
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Alemtuzumab
Availability	Prescription only
Generic	Alemtuzumab
Alemtuzumab Other Names	Alemtuzumab
Related Drugs	Gilenya, Tysabri, Venclexta, Vumerity, rituximab, Rituxan, cyclophosphamide, Copaxone, Imbruvica, Tecfidera
Weight	10mg/ml, 30mg/ml,
Type	Intravenous Solution, Intravenous
Formula	C6468H10066N1732O2005S40
Weight	145453.8 Da
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Alemtuzumab is a monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.

Alemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.

Alemtuzumab is also used to associated treatment for these conditions: Autoimmune Hemolytic Anemia, B-Cell Chronic Lymphocytic Leukemia, Graft Versus Host Disease (GVHD), Kidney Transplant Rejection, Relapsing Remitting Multiple Sclerosis (RRMS), T-Cell Prolymphocytic Leukemia, Conditioning regimens for allogeneic stem cell transplantation therapy

How Alemtuzumab works

Campath binds to the CD52 antigen present on most B and T lymphocytes. This binding leads to antibody-dependent lysis of leukemic cells.

Food Interaction

No interactions found.

Alemtuzumab Drug Interaction

Major: teriflunomide, teriflunomideModerate: aspirin, aspirin, dimethyl fumarate, dimethyl fumarateUnknown: acetaminophen, acetaminophen, charcoal, charcoal, alprazolam, alprazolam, dalfampridine, dalfampridine, pseudoephedrine / triprolidine, pseudoephedrine / triprolidine, interferon beta-1a, interferon beta-1a, sodium iodide, sodium iodide

Alemtuzumab Disease Interaction

Major: cytopeniasModerate: cardiac/pulmonary disease, infections

Volume of Distribution

• 0.18 L/kg

Half Life

~288 hrs

Innovators Monograph

You find simplified version here Alemtuzumab